Published in J Biol Chem on August 31, 2004
Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging | NCT00251615
The ß subunit of voltage-gated Ca2+ channels. Physiol Rev (2010) 2.30
Rem, a member of the RGK GTPases, inhibits recombinant CaV1.2 channels using multiple mechanisms that require distinct conformations of the GTPase. J Physiol (2010) 1.38
Vascular calcium channels and high blood pressure: pathophysiology and therapeutic implications. Vascul Pharmacol (2006) 1.31
New Determinant for the CaVbeta2 subunit modulation of the CaV1.2 calcium channel. J Biol Chem (2008) 1.21
Alanine-scanning mutagenesis defines a conserved energetic hotspot in the CaValpha1 AID-CaVbeta interaction site that is critical for channel modulation. Structure (2008) 1.17
Differential regulated interactions of calcium/calmodulin-dependent protein kinase II with isoforms of voltage-gated calcium channel beta subunits. Biochemistry (2008) 1.08
Functional modularity of the beta-subunit of voltage-gated Ca2+ channels. Biophys J (2007) 1.07
Orientation of the calcium channel beta relative to the alpha(1)2.2 subunit is critical for its regulation of channel activity. PLoS One (2008) 1.02
Regulation of maximal open probability is a separable function of Ca(v)beta subunit in L-type Ca2+ channel, dependent on NH2 terminus of alpha1C (Ca(v)1.2alpha). J Gen Physiol (2006) 1.02
Diversity and developmental expression of L-type calcium channel beta2 proteins and their influence on calcium current in murine heart. J Biol Chem (2009) 1.01
Structure and function of the β subunit of voltage-gated Ca²⁺ channels. Biochim Biophys Acta (2012) 0.94
Two PEST-like motifs regulate Ca2+/calpain-mediated cleavage of the CaVbeta3 subunit and provide important determinants for neuronal Ca2+ channel activity. Eur J Neurosci (2006) 0.94
The guanylate kinase domain of the beta-subunit of voltage-gated calcium channels suffices to modulate gating. Proc Natl Acad Sci U S A (2008) 0.93
Inactivation of L-type calcium channels is determined by the length of the N terminus of mutant beta(1) subunits. Pflugers Arch (2009) 0.89
Atypical properties of a conventional calcium channel beta subunit from the platyhelminth Schistosoma mansoni. BMC Physiol (2008) 0.83
Molecular determinants of the CaVbeta-induced plasma membrane targeting of the CaV1.2 channel. J Biol Chem (2010) 0.83
Disrupting calcium channel expression to lower blood pressure: new targeting of a well-known channel. Mol Interv (2006) 0.82
The calcium channel beta2 (CACNB2) subunit repertoire in teleosts. BMC Mol Biol (2008) 0.81
Gene splicing of an invertebrate beta subunit (LCavβ) in the N-terminal and HOOK domains and its regulation of LCav1 and LCav2 calcium channels. PLoS One (2014) 0.78
Ahnak1 modulates L-type Ca(2+) channel inactivation of rodent cardiomyocytes. Pflugers Arch (2010) 0.78
A drug burden index to define the functional burden of medications in older people. Arch Intern Med (2007) 2.84
Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet (2010) 2.32
Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction. J Biol Chem (2003) 2.20
Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol (2008) 1.78
Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem (2007) 1.77
Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol (2009) 1.58
Differential role of the alpha1C subunit tails in regulation of the Cav1.2 channel by membrane potential, beta subunits, and Ca2+ ions. J Biol Chem (2005) 1.40
CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol (2012) 1.40
The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci (2013) 1.38
Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats. FASEB J (2006) 1.36
Voltage-gated mobility of the Ca2+ channel cytoplasmic tails and its regulatory role. J Biol Chem (2002) 1.30
New Determinant for the CaVbeta2 subunit modulation of the CaV1.2 calcium channel. J Biol Chem (2008) 1.21
Drug burden index score and functional decline in older people. Am J Med (2009) 1.19
Examining intracellular organelle function using fluorescent probes: from animalcules to quantum dots. Circ Res (2004) 1.14
Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel alpha1C subunit. Proc Natl Acad Sci U S A (2006) 1.14
Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol. Chirality (2006) 1.14
Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. J Pharmacol Exp Ther (2002) 1.12
Molecular determinants of voltage-dependent slow inactivation of the Ca2+ channel. J Biol Chem (2001) 1.11
Drug Burden Index for international assessment of the functional burden of medications in older people. J Am Geriatr Soc (2014) 1.09
Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu Rev Pharmacol Toxicol (2012) 1.08
Voltage-gated rearrangements associated with differential beta-subunit modulation of the L-type Ca(2+) channel inactivation. Biophys J (2004) 1.05
Activation of protein kinase C augments T-type Ca2+ channel activity without changing channel surface density. J Physiol (2006) 1.02
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol (2012) 1.01
Modulation of Ca2+ signalling in rat atrial myocytes: possible role of the alpha1C carboxyl terminal. J Physiol (2003) 1.00
Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther (2004) 0.96
Effect of Ca(v)beta subunits on structural organization of Ca(v)1.2 calcium channels. PLoS One (2009) 0.95
Analysis of functional signaling domains from fluorescence imaging and the two-dimensional continuous wavelet transform. Biophys J (2007) 0.95
Drug burden index and beers criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol (2012) 0.94
Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. Food Drug Law J (2008) 0.93
Use of wavelet and fast Fourier transforms in pharmacodynamics. J Pharmacol Exp Ther (2006) 0.92
Molecular rearrangements of the Kv2.1 potassium channel termini associated with voltage gating. J Biol Chem (2006) 0.91
Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics (2002) 0.91
Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf (2015) 0.91
Calmodulin-dependent gating of Ca(v)1.2 calcium channels in the absence of Ca(v)beta subunits. Proc Natl Acad Sci U S A (2008) 0.90
Microdomain organization and frequency-dependence of CREB-dependent transcriptional signaling in heart cells. FASEB J (2011) 0.88
Revision of instructions to authors for pharmacology research and perspectives: enhancing the quality and transparency of published work. Pharmacol Res Perspect (2015) 0.87
A pilot randomized clinical trial utilizing the drug burden index to reduce exposure to anticholinergic and sedative medications in older people. Ann Pharmacother (2010) 0.87
A 2012 Workshop: Vaccine and Drug Ontology in the Study of Mechanism and Effect (VDOSME 2012). J Biomed Semantics (2012) 0.87
Effect of angiotensin-converting enzyme insertion/deletion polymorphism DD genotype on high-frequency heart rate variability in African Americans. Am J Cardiol (2003) 0.87
Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults. J Gerontol A Biol Sci Med Sci (2011) 0.87
Molecular remodeling of ion channels, exchangers and pumps in atrial and ventricular myocytes in ischemic cardiomyopathy. Channels (Austin) (2010) 0.86
Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther (2003) 0.86
Effects of the physical work environment on physiological measures of stress. Eur J Cardiovasc Prev Rehabil (2010) 0.86
Caloric restriction reduces age-related pseudocapillarization of the hepatic sinusoid. Exp Gerontol (2007) 0.85
Oligomerization of Cavbeta subunits is an essential correlate of Ca2+ channel activity. FASEB J (2010) 0.85
Geriatric drug evaluation: where are we now and where should we be in the future? Arch Intern Med (2011) 0.84
Identification of plasma membrane macro- and microdomains from wavelet analysis of FRET microscopy. Biophys J (2005) 0.82
Functional properties of the CaV1.2 calcium channel activated by calmodulin in the absence of alpha2delta subunits. Channels (Austin) (2009) 0.78
Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network. J Pharm Sci (2005) 0.78
Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects. Am Heart J (2002) 0.77
Selective fluorophore-assisted light inactivation of voltage-gated calcium channels. Channels (Austin) (2012) 0.76
Reducing drugs in older adults is more. Arch Intern Med (2011) 0.75
Cardiac phenotype induced by a dysfunctional α 1C transgene: a general problem for the transgenic approach. Channels (Austin) (2011) 0.75
Advice on statistical analysis, and new journal guidance for experimental design and analysis. Pharmacol Res Perspect (2015) 0.75
Change in criteria for USP dissolution performance verification tests. AAPS PharmSciTech (2009) 0.75
Measures of drug toxicity in older adults. Arch Intern Med (2008) 0.75
Kullback-Leibler clustering of continuous wavelet transform measures of heart rate variability. Biomed Sci Instrum (2004) 0.75
Metrologic approaches to setting acceptance criteria: unacceptable and unusual characteristics. J Pharm Biomed Anal (2008) 0.75
Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clin Pharmacol Ther (2004) 0.75